Skip to main content
Log in

Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy

  • Original Papers
  • Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

One possible explanation for the failure of the high concentrations of cytotoxic agents achieved following intraperitoneal (i.p.) drug delivery to produce a favorable response in patients with ovarian cancer is the inability of the drug-containing fluid to be adequately distributed throughout the peritoneal cavity, usually because of intraabdominal adhesion formation. To evaluate the influence of the severity of adhesions, observed at the time of laparotomy performed immediately preceding the initiation of i.p. therapy, on the ability to achieve a surgically defined complete response (S-CR), we retrospectively reviewed the operative reports of 70 patients with small-volume residual ovarian cancer treated on one of three phase-2 salvage i.p. trials at the Memorial Sloan-Kettering Cancer Center. The S-CR rate in the 36 patients withlimited adhesion formation observed upon entering the peritoneal cavity was 28%, compared to 35% in the 34 patients withextensive adhesions (P>0.05). In 33 patients treated with a phase-2 cisplatin-based i.p. program, who had previously responded to systemic platinum, 47% (8/17) and 44% (7/16) of those with limited and extensive adhesions, respectively, achieved a S-CR (P>0.05). We conclude that the presence of extensive adhesions observed within the peritoneal cavity at the time of a laparotomy performed immediately prior to the initiation of i.p. therapy does not have a negative impact on the potential to achieve an S-CR, assuming it is technically feasible to lyse all significant adhesions prior to the completion of the operative procedure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Dunnick NR, Jones RB, Doppmen JL, Speyer J, Myers CE (1979) Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR 133:221–223

    PubMed  Google Scholar 

  • Howell SB, Pfeifle CE, Wung CE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851

    PubMed  Google Scholar 

  • Levenback C, Curtin J, Rubin S, Yeh S, Hoskins W, Chapman D, Jones W, Hakes T, Markman M, Reichman B, Lewis JL Jr (1989) A longitudinal study of the distribution of intraperitoneally administered fluids as determined by radionuclide scanning (abstract). In: Proceedings of the International Gynecological Cancer Society, vol 2, P 161

  • Markman M (1986) Intraperitoneal anti-neoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 13:219–242

    PubMed  Google Scholar 

  • Markman M (1991) Intraperitoneal chemotherapy. Semin Oncol 18:248–254

    PubMed  Google Scholar 

  • Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1990) Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 8:146–150

    PubMed  Google Scholar 

  • Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Yordan EL Jr, Eriksson J, Lewis JL Jr (1991 a) Intraperitoneal cisplatin and cytarabine in the treatment of refractory or rcurrent ovarian carcinoma. J Clin Oncol 9:204–210

    PubMed  Google Scholar 

  • Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, Almadrones L, Hoskins W (1991 b) Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to systemic cisplatin. J Clin Oncol (in press)

  • Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, Almadrones L, Ochoa M Jr, Chapman D, Saigo P, Lewis JL Jr (1989) Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol 7:1327–1332

    PubMed  Google Scholar 

  • Rosenshein N, Blake D, McIntyre PA, Parmley T, Natarajan TK, Dvornicky J, Nickoloff E (1978) The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol 6:106–110

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported in part by the Avon Program in Ovarian Cancer, Memorial Sloan-Kettering Cancer Center

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M., Jones, W., Lewis, J.L. et al. Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy. J Cancer Res Clin Oncol 118, 163–165 (1992). https://doi.org/10.1007/BF01187507

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01187507

Key words

Navigation